Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on December 17, 2007

Circulation. 2007
Published online before print December 17, 2007, doi: 10.1161/CIRCULATIONAHA.107.715698
A more recent version of this article appeared on January 15, 2008
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
117/2/176    most recent
CIRCULATIONAHA.107.715698v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kamstrup, P. R.
Right arrow Articles by Nordestgaard, B. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kamstrup, P. R.
Right arrow Articles by Nordestgaard, B. G.
Related Collections
Right arrow Risk Factors
Right arrow Acute myocardial infarction
Right arrow Epidemiology
Right arrowRelated Article

Submitted on May 21, 2007
Accepted on October 26, 2007

Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population. The Copenhagen City Heart Study

Pia R. Kamstrup MD, Marianne Benn MD, PhD, Anne Tybjærg-Hansen MD, DMSc, and Børge G. Nordestgaard MD, DMSc*

From the Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital (P.R.K., M.B., B.G.N.); Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital (A.T.-H.); and the Copenhagen City Heart Study, Bispebjerg Hospital, Copenhagen University Hospital, University of Copenhagen (A.T.-H., B.G.N.), Copenhagen, Denmark.

* To whom correspondence should be addressed. E-mail: brno{at}heh.regionh.dk.

Background—Elevated lipoprotein(a) levels are associated with myocardial infarction (MI) in some but not all studies. Limitations of previous studies include lack of risk estimates for extreme lipoprotein(a) levels, measurements in long-term frozen samples, no correction for regression dilution bias, and lack of absolute risk estimates in the general population. We tested the hypothesis that extreme lipoprotein(a) levels predict MI in the general population, measuring levels shortly after sampling, correcting for regression dilution bias, and calculating hazard ratios and absolute risk estimates.

Methods and Results—We examined 9330 men and women from the general population in the Copenhagen City Heart Study. During 10 years of follow-up, 498 participants developed MI. In women, multifactorially adjusted hazard ratios for MI for elevated lipoprotein(a) levels were 1.1 (95% CI, 0.6 to 1.9) for 5 to 29 mg/dL (22nd to 66th percentile), 1.7 (1.0 to 3.1) for 30 to 84 mg/dL (67th to 89th percentile), 2.6 (1.2 to 5.9) for 85 to 119 mg/dL (90th to 95th percentile), and 3.6 (1.7 to 7.7) for ≥120 mg/dL (>95th percentile) versus levels <5 mg/dL (<22nd percentile). Equivalent values in men were 1.5 (0.9 to 2.3), 1.6 (1.0 to 2.6), 2.6 (1.2 to 5.5), and 3.7 (1.7 to 8.0). Absolute 10-year risks of MI were 10% and 20% in smoking, hypertensive women aged >60 years with lipoprotein(a) levels of <5 and ≥120 mg/dL, respectively. Equivalent values in men were 19% and 35%.

Conclusions—We observed a stepwise increase in risk of MI with increasing levels of lipoprotein(a), with no evidence of a threshold effect. Extreme lipoprotein(a) levels predict a 3- to 4-fold increase in risk of MI in the general population and absolute 10-year risks of 20% and 35% in high-risk women and men.


Key words: coronary disease • lipoproteins • myocardial infarction


Related Article:

Clinical Summaries
Circulation 2008 117: 127. [Full Text]